Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis

TitleEvolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis
Publication TypeJournal Article
Year of Publication2017
AuthorsGeorgiadis P., Liampa I., Hebels D.G, Krauskopf J., Chatziioannou A., Valavanis I., de Kok T, Kleinjans J.CS, Bergdahl I.A, Melin B., Spaeth F., Palli D., Vermeulen R.CH, Vlaanderen J., Chadeau-Hyam M., Vineis P., Kyrtopoulos S.A
JournalBMC Genomics
Volume18
Pagination728
Date PublishedSep 13
ISBN Number1471-2164
Accession Number28903739
Keywords*Gene Expression Profiling, Biomarkers of risk, Biomarkers, Tumor/*genetics, DNA Methylation, Epigenomics, Gene Expression Regulation, Neoplastic, Humans/*genetics, Leukemia, Lymphocytic, Chronic, B-Cell/blood/*diagnosis/*genetics, MicroRNAs/genetics, miRNA, Molecular Epidemiology, Prognosis, Prospective cohort, Time Factors, Transcriptomics
Abstract

BACKGROUND: B-cell chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. It often follows an indolent course and is preceded by monoclonal B-cell lymphocytosis, an asymptomatic condition, however it is not known what causes subjects with this condition to progress to CLL. Hence the discovery of prediagnostic markers has the potential to improve the identification of subjects likely to develop CLL and may also provide insights into the pathogenesis of the disease of potential clinical relevance. RESULTS: We employed peripheral blood buffy coats of 347 apparently healthy subjects, of whom 28 were diagnosed with CLL 2.0-15.7 years after enrollment, to derive for the first time genome-wide DNA methylation, as well as gene and miRNA expression, profiles associated with the risk of future disease. After adjustment for white blood cell composition, we identified 722 differentially methylated CpG sites and 15 differentially expressed genes (Bonferroni-corrected p < 0.05) as well as 2 miRNAs (FDR < 0.05) which were associated with the risk of future CLL. The majority of these signals have also been observed in clinical CLL, suggesting the presence in prediagnostic blood of CLL-like cells. Future CLL cases who, at enrollment, had a relatively low B-cell fraction (<10%), and were therefore less likely to have been suffering from undiagnosed CLL or a precursor condition, showed profiles involving smaller numbers of the same differential signals with intensities, after adjusting for B-cell content, generally smaller than those observed in the full set of cases. A similar picture was obtained when the differential profiles of cases with time-to-diagnosis above the overall median period of 7.4 years were compared with those with shorted time-to-disease. Differentially methylated genes of major functional significance include numerous genes that encode for transcription factors, especially members of the homeobox family, while differentially expressed genes include, among others, multiple genes related to WNT signaling as well as the miRNAs miR-150-5p and miR-155-5p. CONCLUSIONS: Our findings demonstrate the presence in prediagnostic blood of future CLL patients, more than 10 years before diagnosis, of CLL-like cells which evolve as preclinical disease progresses, and point to early molecular alterations with a pathogenetic potential.

Short TitleBMC GenomicsBMC Genomics
Alternate JournalBMC genomics